RASHED, G., NASR, M., ABD EL HAMID, A., ALY, N., BARAKAT, A., AHMED, K., YOUSSIF, S., OMAR, G. (2023). ASSESMENT OF THE THERAPUTIC EFECT OF LATE AZITHROMYCIN TREATMENT ON CHRONIC MURINE TOXOPLASMOSIS. test, 53(3), 491-498. doi: 10.21608/jesp.2023.331734
GEHAN A. RASHED; MONA E. NASR; ATEF H. ABD EL HAMID; NAGWA S. M. ALY; ASHRAF M. A. BARAKAT; KAWKAB A. AHMED; SAFAA H. YOUSSIF; GHADA H. OMAR. "ASSESMENT OF THE THERAPUTIC EFECT OF LATE AZITHROMYCIN TREATMENT ON CHRONIC MURINE TOXOPLASMOSIS". test, 53, 3, 2023, 491-498. doi: 10.21608/jesp.2023.331734
RASHED, G., NASR, M., ABD EL HAMID, A., ALY, N., BARAKAT, A., AHMED, K., YOUSSIF, S., OMAR, G. (2023). 'ASSESMENT OF THE THERAPUTIC EFECT OF LATE AZITHROMYCIN TREATMENT ON CHRONIC MURINE TOXOPLASMOSIS', test, 53(3), pp. 491-498. doi: 10.21608/jesp.2023.331734
RASHED, G., NASR, M., ABD EL HAMID, A., ALY, N., BARAKAT, A., AHMED, K., YOUSSIF, S., OMAR, G. ASSESMENT OF THE THERAPUTIC EFECT OF LATE AZITHROMYCIN TREATMENT ON CHRONIC MURINE TOXOPLASMOSIS. test, 2023; 53(3): 491-498. doi: 10.21608/jesp.2023.331734

ASSESMENT OF THE THERAPUTIC EFECT OF LATE AZITHROMYCIN TREATMENT ON CHRONIC MURINE TOXOPLASMOSIS

Journal of the Egyptian Society of Parasitology
Article 10, Volume 53, Issue 3, December 2023, Pages 491-498    PDF (1.01 M)
Document Type: Original Article
DOI: 10.21608/jesp.2023.331734
Authors
GEHAN A. RASHED1; MONA E. NASR1; ATEF H. ABD EL HAMID1; NAGWA S. M. ALY1; ASHRAF M. A. BARAKAT2; KAWKAB A. AHMED3; SAFAA H. YOUSSIF1; GHADA H. OMAR1
1Department of Parasitology, Faculty of Medicine, Benha University
2Department of Zoonotic Diseases, National Research Centre, Cairo 12622, Egypt
3Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt
Abstract
Toxoplasmosis is a widespread, neglected disease with significant morbidity and mortality. The current
study aimed to investigate the potential effectiveness of azithromycin against the cystogenic Me
49 nonvirulent strain of Toxoplasma gondii after the 6th week post-infection (PI) in chronically infected
mice. Fifty laboratory-bred female Swiss albino mice were divided into five groups: G1: Non-
Infected, G2: Infected non-treated, G3: Infected and treated by azithromycin 200 mg/kg after the 6th
week PI for 3 days, G4: Infected and treated by azithromycin 200 mg/kg after the 6th week PI for 10
days and G5: Infected and treated by spiramycin 200 mg/kg after the 6th week PI for 2 weeks, brain
cysts number, size and histopathological changes were evaluated after 2 months.
The results showed that treating mice after the 6th week post-infection with azithromycin for 10 days
reduced number and size of brain cysts by 64% & 30%, respectively, but without significant difference
as compared with spiramycin-treated ones. Azithromycin treatment for 3 days achieved a greater reduction
(34%) in brain cyst size than the group treated with azithromycin for 10 days. But, it caused
the least reduction in brain cyst number (10%). Azithromycin treatment for 10 days improved the histopathological
changes in cerebral toxoplasmosis.
Keywords
Mice; Azithromycin; Spiramycin; Toxoplasma gondii; Treatment
Statistics
Article View: 76
PDF Download: 166